SK Pharmteco Inc.

SK pharmteco Inc. is a global contract development and manufacturing organization (CDMO) headquartered in Rancho Cordova, California, USA. As a subsidiary of SK Inc., the company's core mission is to enable its partners with advanced technology and expertise to bring life-saving therapies to patients, aiming to be the most trusted global partner in the delivery of innovative medicines.

The company specializes in providing comprehensive services for the pharmaceutical industry, including process and analytical method development, optimization, validation, analytical testing, and commercial production. Its key offerings span small molecule active pharmaceutical ingredients (APIs), advanced intermediates, and cell and gene therapy technologies. SK pharmteco possesses expertise in specialized areas such as energetic chemistry, continuous flow processing, high potency APIs, controlled substances, particle engineering, and viral vectors (AAV and lentiviral).

SK pharmteco operates as a leading global CDMO with a network of CGMP facilities across the United States, Europe, and South Korea. Joerg Ahlgrimm serves as the CEO. In December 2024, the company secured a significant $1.4 billion deal for GLP-1 obesity treatments and unified its various brands, including SK biotek, AMPAC Fine Chemicals, and Yposkesi, under the single SK pharmteco identity. The company is actively expanding its manufacturing capabilities, with a $260 million peptide production plant in Sejong, South Korea, slated to open in 2026, and a $6.1 million investment in its Rancho Cordova facility for peptide synthesis and purification, with new labs and facilities becoming operational in 2026. While privately held, SK pharmteco has previously explored plans for an initial public offering (IPO) on exchanges like Nasdaq or Kosdaq, with a targeted listing for pre-IPO funding in 2025.